Aaron S, Davis P, Percy J
J Rheumatol. 1985 Oct;12(5):897-9.
The records of 25 patients who developed neutropenia (granulocyte count less than or equal to 2500 mm3) while receiving intramuscular gold sodium aurothiomalate (GSTM) were reviewed. According to commonly used clinical criteria, 3 patients developed Felty's syndrome, 8 gold myelotoxicity, and 14 mild, chronic benign granulocytopenia. Myelotoxicity occurred exclusively during the initial course of therapy (less than or equal to 1 g GSTM). Twelve of the patients with chronic granulocytopenia continue to receive gold without other signs of serious toxicity. We conclude that Felty's syndrome can develop during gold administration, and that many patients may continue safely to receive gold despite neutropenia.
回顾了25例在接受肌肉注射硫代苹果酸金钠（GSTM）时出现中性粒细胞减少（粒细胞计数小于或等于2500/mm³）的患者记录。根据常用临床标准，3例患者出现费尔蒂综合征，8例出现金制剂骨髓毒性，14例出现轻度慢性良性粒细胞减少。骨髓毒性仅发生在治疗初期（GSTM剂量小于或等于1g）。12例慢性粒细胞减少患者继续接受金制剂治疗，无其他严重毒性迹象。我们得出结论，在使用金制剂过程中可能会发生费尔蒂综合征，并且许多患者尽管出现中性粒细胞减少仍可安全地继续接受金制剂治疗。
